Summary
Eli Lilly & Company (LLY) filed an 8-K on January 31, 2007, announcing the completion of its acquisition of ICOS Corporation for approximately $2.3 billion, or $34 per share. This strategic move significantly expands Lilly's portfolio, particularly in key therapeutic areas. The filing also includes a press release detailing Lilly's fourth quarter and full-year 2006 financial results. Notably, the company provided financial expectations for 2007, offering both GAAP and adjusted earnings per share guidance. Lilly emphasizes its use of non-GAAP financial measures to provide a clearer view of ongoing operational performance, excluding charges related to product liability, asset impairments, restructuring, and accounting changes. Investors should carefully consider these adjusted figures alongside GAAP results to understand the company's underlying business trends and future outlook.
Key Highlights
- 1Completed acquisition of ICOS Corporation for approximately $2.3 billion ($34/share) on January 29, 2007.
- 2The acquisition is expected to enhance Lilly's product portfolio and market presence.
- 3Announced fourth quarter and full-year 2006 financial results.
- 4Provided full-year 2007 financial expectations, including both GAAP and adjusted EPS guidance.
- 5Utilizes non-GAAP financial measures (adjusted net income, adjusted EPS) for enhanced operational clarity.
- 6Adjusted results exclude significant charges such as product liability, asset impairment, restructuring, and accounting changes from prior periods.
- 7Management uses non-GAAP measures internally for performance evaluation and resource allocation.